IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. lowered its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 5.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,746,480 shares of the medical research company’s stock after selling 99,231 shares during the period. JPMorgan Chase & Co. owned about 0.96% of IQVIA worth $343,201,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Synergy Asset Management LLC bought a new position in shares of IQVIA during the fourth quarter worth about $33,000. Lee Danner & Bass Inc. acquired a new position in IQVIA during the 4th quarter valued at about $44,000. Zions Bancorporation N.A. grew its position in IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock worth $47,000 after purchasing an additional 85 shares during the last quarter. Versant Capital Management Inc increased its stake in shares of IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 93 shares during the period. Finally, SBI Securities Co. Ltd. bought a new stake in shares of IQVIA during the fourth quarter valued at approximately $60,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently commented on IQV. Citigroup lowered their target price on IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. William Blair restated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Bank of America decreased their target price on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Royal Bank of Canada restated an “outperform” rating and set a $270.00 price target on shares of IQVIA in a research report on Monday, February 10th. Finally, UBS Group decreased their price objective on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a report on Friday, February 7th. Five research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Price Performance

NYSE IQV opened at $177.27 on Monday. IQVIA Holdings Inc. has a 1 year low of $176.03 and a 1 year high of $253.84. The stock’s 50-day moving average price is $193.15 and its two-hundred day moving average price is $206.05. The company has a market cap of $31.25 billion, a PE ratio of 23.64, a PEG ratio of 1.99 and a beta of 1.50. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.